MAPT and Alzheimer disease: Cerebral insulin resistance results in disinhibition of glycogen synthase kinase-3β (GSK-3β) that promotes tau hyperphosphorylation and amyloidogenic processing of the amyloid precursor protein (APP); thus, disrupted insulin signaling is linked to the classical AD pathologies [8,9,10].